Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830039 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL9557207 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL6900424 | 0.87 | PPID (0.50) | ALDH1A1FOLH1TYR | |
| SCHEMBL9830412 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL9830409 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL18190834 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL6824840 | 0.84 | PLA2G2A (0.55) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL2455888 | 0.84 | PLA2G2A (0.55) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL1068731 | 0.84 | PLA2G2A (0.55) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL7769892 | 0.84 | PPID (0.42) | ALDH1A1FOLH1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AB (SE) | 2020-12-24 | — | — | US | disclosed |
| EP-0525584-B1 | 6-Oxo-azepinoindole derivatives, process and intermediates for their preparation and medicaments containing them | SOLVAY PHARM GMBH (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5272143-A | 6-oxoazepinoindole compounds, and pharmaceutical compositions containing them | KALI-CHEMIE PHARMA GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| EP-0525584-A1 | 6-Oxo-azepinoindole derivatives, process and intermediates for their preparation and medicaments containing them | Kali-Chemie Pharma GmbH (DE) | 1993-02-03 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4977277-A | INTERMEDIATES FOR RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-12-11 | — | — | US | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | PNP, NUDT1, TYMP | ALDH1A1 3402/4885MEN1 2633/4885LMNA 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.